Evolving perspectives of the role of novel agents in androgen-independent prostate cancer

Indian Journal of Urology

Volumn 24, Issue 3, 2008, Pages 303-308

  Kalmadi, Sujith ^a   Raghavan, Derek ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bio markers; Chemotherapy; Prostate neoplasm; Quality of life

Indexed keywords

EID: 50949097756     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.42609     Document Type: Review

References (32)

1. Huggins C, Hodges C V. Studies on prostatic cancer, I: The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.
2. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A. Androgen receptors in prostate cancer. J Urol 2003;170:1363-9.
3. Isaacs J. Apoptosis: Translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000;92:1367-9.
4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
5. Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R, et al. Prognostic factors in stage D2 prostate cancer: Important implications for future trials: Results of a cooperative intergroup study (INT 0036): The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994;21:613-9.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
7. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
8. Petrylak D P, Ankerst D P, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-21.
9. Raghavan D. Chemotherapy for prostate cancer: Small steps or leaps and bounds? No huzzahs just yet! Br J Cancer 2004;91:1003-4.
10. Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels <10 ng/mL: The "PSA negative" patients. Cancer 2003;98:2362-7.
11. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
12. Kantoff P W, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13.
13. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439-43.
14. Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: High subjective and objective response in patients with symptomatic metastases. J Urol 2005;174:1808-13.
15. Petrylak D P, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
16. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
17. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2-9.
18. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60.
19. Beer T, Ryan C, et al. Interim results from ASCENT: A double blinded randomized study of high dose calcitriol plus docetaxel versus placebo in AIPC. ASCO; 2005.
20. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
21. Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology 2006;68:244-8.
22. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
23. Kalmadi SR, Baz R, Mahindra A. Lenalidomide: The emerging role of a novel targeted agent in malignancies. Drugs Today 2007;43:85-95.
24. Nelson JB, Chan-Tack K, Hedican S P, Magnuson SR, Opgenorth TJ, Bova GS, et al. Endothelin-1 production and decreased endothelin B receptor expression in prostate cancer. Cancer Res 1996;56:663-8.
25. Carducci M, Padley RJ. Effects of atrasentan on disease progression and biologic markers in men with metastatic HRPC. American Society of Clinical Oncology; 2004.
26. Vogelzang NJ, Nelson JB, Schulman CC. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. Proc. Annual Scientific Meeting, American Society of Clinical Oncology; 2005.
27. Arlen PM, Dahut WL, Gulley JL. Immunotherapy for prostate cancer: What's the future? Hematol Oncol Clin North Am 2006;20:965-83.
28. Small EJ, Schellhammer P F. Immunotherapy (APC 8015) for AIPC: Final survival data from a phase 3 randomized placebo controlled trial. Am Soc Clin Oncol Prostate Ca Symposium; 2005.
29. Small EJ, Higano C. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line in patients with AIPC. ASCO Annual Meeting; 2004.
30. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic and therapeutic implications. Cancer 1992;70:254-68.
31. rd ed; 2006.
32. Papandreou CN, Daliani DD, Thall P F, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80.